



Viral Epidemiology Snapshot: May 1-7, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	618	123	19.9%
Flu B	618	1	0.2%
RSV	253	6	2.4%
CoV-2 PUI	975	117	12.0%
CoV-2 Surveillance	249	2	0.8%


Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	254	23	9.1%
Coronavirus 229E	252	1	0.4%
Coronavirus HKU1	252	0	0.0%
Coronavirus NL63	252	8	3.2%
Coronavirus OC43	252	12	4.8%
Metapneumovirus	252	21	8.3%
Rhinovirus/Enterovirus	252	77	30.6%
Parainfluenza 1	252	0	0.0%
Parainfluenza 2	252	0	0.0%
Parainfluenza 3	252	21	8.3%
Parainfluenza 4	252	1	0.4%

Flu A Subtyping

2009 H1N1	0
Seasonal H1	0
Seasonal H3	28
No Subtype	95
Pending subtype	0


Flu, RSV, & CoV-2 Trends



This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning Valley laboratories. It also includes Point-of-Care tests (POCT) for influenza and SARS-CoV-2 (as of 2/20) performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

CoV-2 Positivity Rate Trends



Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of 10/31, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.

